01 6Saxenda
02 10Victoza
03 5Xultophy
04 1of Which Saxenda
05 1of which Saxenda
Main Therapeutic Indication : Nutritional Deficiency
Currency : USD
2020 Revenue in Millions : 912
2019 Revenue in Millions : 924
Growth (%) : -1
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 3,049
2019 Revenue in Millions : 3,567
Growth (%) : -15
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 398
2019 Revenue in Millions : 359
Growth (%) : 11
Main Therapeutic Indication : Nutritional Deficiency
Currency : USD
2021 Revenue in Millions : 1,280
2020 Revenue in Millions : 897
Growth (%) : 50
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 2,294
2020 Revenue in Millions : 3,000
Growth (%) : -20
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 405
2020 Revenue in Millions : 391
Growth (%) : 9
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 410
2021 Revenue in Millions : 405
Growth (%) : 1
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 1,797
2021 Revenue in Millions : 2,294
Growth (%) : -22
Main Therapeutic Indication : Nutritional Deficiency
Currency : USD
2022 Revenue in Millions : 1,557
2021 Revenue in Millions : 1,069
Growth (%) : 46
Main Therapeutic Indication : Diabetes
Currency : USD
2023 Revenue in Millions : 1,259
2022 Revenue in Millions : 1,797
Growth (%) : -30
